- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-1934
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder ; volume:36 ; number:11 ; day:3 ; month:10 ; year:2022 ; pages:1239 ; date:11.2022
CNS drugs ; 36, Heft 11 (3.10.2022), 1239, 11.2022
- Creator
-
Nie, Tina
Blair, Hannah A.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40263-022-00957-7
- URN
-
urn:nbn:de:101:1-2023012621103428827975
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:32 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nie, Tina
- Blair, Hannah A.
- SpringerLink (Online service)
Other Objects (12)
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Emerging treatments for neuromyelitis optica spectrum disorder
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Unveiling the retinal secrets of neuromyelitis optica spectrum disorder
Health utilities and costs for neuromyelitis optica spectrum disorder
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder
CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder
Functional disability of neuromyelitis optica spectrum disorder in Brazil
Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience
Neuromyelitis Optica Spectrum Disorder Coinciding with Spinocerebellar Ataxia Type 31
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Emerging treatments for neuromyelitis optica spectrum disorder
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Unveiling the retinal secrets of neuromyelitis optica spectrum disorder
Health utilities and costs for neuromyelitis optica spectrum disorder
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder
CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder
Functional disability of neuromyelitis optica spectrum disorder in Brazil
Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience
Neuromyelitis Optica Spectrum Disorder Coinciding with Spinocerebellar Ataxia Type 31
Correction to: Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Emerging treatments for neuromyelitis optica spectrum disorder
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate
Unveiling the retinal secrets of neuromyelitis optica spectrum disorder
Health utilities and costs for neuromyelitis optica spectrum disorder
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder
CD22 blockade exacerbates neuroinflammation in Neuromyelitis optica spectrum disorder
Functional disability of neuromyelitis optica spectrum disorder in Brazil
Neuromyelitis optica and neuromyelitis optica spectrum disorder: Natural history and long-term outcome, an Indian experience